Search

Displaying results 2291 - 2300 of 2481 in total
  1. Drug

    Dasabuvir

    go.drugbank.com/drugs/DB09183
    Approved

    Dasabuvir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is ...

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  2. Drug

    Rivoglitazone

    go.drugbank.com/drugs/DB09200
    Investigational

    Rivoglitazone (INN) is a thiazolidinedione undergoing research for use in the treatment of type 2 diabetes. It is being developed by Daiichi Sankyo Co.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 Inhibitors
  3. Drug

    Dexibuprofen

    go.drugbank.com/drugs/DB09213
    ApprovedWithdrawn

    Dexibuprofen, S(+)-ibuprofen, is a non-steroidal anti-inflammatory drug (NSAID). It is a pharmacologically effective enantiomer of racemic ibuprofen that differs in physicochemical properties. It is proposed to be more pharmacologically ...

    Synonyms: (+)-(S)-p-isobutylhydratropic acidCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 Substrates
  4. Drug

    Azelnidipine

    go.drugbank.com/drugs/DB09230
    Investigational

    Azelnidipine is a dihydropyridine calcium channel blocker. It is marketed by Daiichi-Sankyo pharmaceuticals, Inc. in Japan. It has a gradual onset of action and produces a long-lasting decrease in blood pressure, with only a small increa...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  5. Drug

    Lacidipine

    go.drugbank.com/drugs/DB09236
    Approved

    Lacidipine is a lipophilic dihydropyridine calcium antagonist with an intrinsically slow onset of activity. Due to its long duration of action, lacidipine does not lead to reflex tachycardia . It displays specificity in the vascular smoo...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  6. Drug

    Levamlodipine

    go.drugbank.com/drugs/DB09237
    ApprovedInvestigational

    Levamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of amlodipine, an antihypertensive medication. Levamlodipine belongs to the dihydropyridine group of calcium channel blockers. This medication was first ...

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  7. Drug

    Manidipine

    go.drugbank.com/drugs/DB09238
    ApprovedInvestigationalWithdrawn

    Manidipine (INN) is a calcium channel blocker (dihydropyridine type) that is used clinically as an antihypertensive. It is selective for vasculature and does not produce effects on the heart at clinically relevant dosages.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 Inhibitors
  8. Drug

    Niguldipine

    go.drugbank.com/drugs/DB09239
    Experimental

    Niguldipine is a calcium channel blocker drug (CCB) with a1-adrenergic antagonist properties.

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  9. Drug

    Niludipine

    go.drugbank.com/drugs/DB09240
    Experimental

    Niludipine is a calcium channel blocker.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  10. Drug

    Lumacaftor

    go.drugbank.com/drugs/DB09280
    ApprovedInvestigational

    Mutations in the CFTR gene result in altered production, misfolding, or function of the CFTR protein and consequently abnormal fluid and ion transport across cell membranes. … [A20298, A20299] As a result, CF patients produce thick, sticky mucus that clogs the ducts of organs where it is produced making patients more susceptible to infections, lung damage, pancreatic insufficiency

    Categories: Cytochrome P-450 CYP2B6 Inducers, P-glycoprotein inducers